Common questions about Tace (FAQ)
Q: Is TACE considered a cure for liver cancer or a different type of treatment?
Official treatment guidelines describe TACE as a locoregional therapy. It is generally not considered a complete cure for liver cancer but may be used to help control tumor growth, reduce tumor size, or serve as a 'bridge' treatment to prepare a patient for potential curative options such as surgery or a liver transplant.
Q: What is the difference between TACE and TAE (Transarterial Embolization)?
TACE, or chemoembolization, is a dual treatment that involves both a chemotherapy drug and a blood-flow blocking material. Transarterial Embolization (TAE) is a similar procedure that uses only the material to block the blood supply, without the addition of a chemotherapy agent.
Q: How is TACE different from TARE (Transarterial Radioembolization) or SIRT?
TARE (Transarterial Radioembolization), sometimes called SIRT, uses microspheres containing a radioactive element like Yttrium-90 to target tumors with internal radiation. TACE, in contrast, targets the tumor using chemotherapy agents delivered along with blood-flow-blocking materials.
Q: What chemotherapy drugs are typically used as part of the TACE procedure?
Official documents indicate that the specific chemotherapy agents used can vary. Common agents utilized in the procedure, either alone or in combination, include Doxorubicin and Cisplatin. When Drug-Eluting Beads (DEB-TACE) are used, Doxorubicin is a frequently approved drug choice.
Q: Is TACE used to treat liver metastasis from other cancers like colorectal or breast cancer?
Studies and official information indicate TACE has been examined for liver tumors that have spread from other primary cancer sites (known as metastases). While evidence is strongest for primary liver cancer, TACE has been used for metastases originating from cancers such as colorectal and neuroendocrine tumors.
Q: What are the chances of hair loss from the chemotherapy used in TACE?
Because TACE is designed to localize the chemotherapy agent primarily within the liver, systemic side effects like hair loss are often reported as minimal or mild. The localized delivery method is intended to reduce the drug's exposure elsewhere in the body.
Q: What interactions can happen if I take blood thinners before or after TACE?
The primary concern when taking blood-thinning medications before the procedure is the risk of bleeding at the catheter insertion site. Official patient preparation guidelines often indicate that certain blood-thinning drugs should be discontinued for a defined period before TACE to minimize this risk.
Q: What kind of activities are restricted in the first 48 to 72 hours post-TACE?
Immediately following the procedure, patients are often instructed to remain in bed and limit physical activity for several hours. While patients are generally advised to rest and should be able to resume most normal activities within about a week, specific restrictions related to lifting or strenuous activity are determined by the managing clinician based on individual recovery needs.
Q: What is the most common complication or risk associated with TACE?
Official reports indicate the most common reaction is Post-Embolization Syndrome (PES), which is reported to be experienced by a high percentage of patients. PES is characterized by transient symptoms like fever, pain, nausea, and vomiting. Serious complications, such as liver failure or infection, are reported to occur in a small percentage of cases.
Q: Are there any risks related to the catheter insertion site (groin or wrist)?
The procedure requires a small incision to insert a catheter, usually at the groin or wrist. Uncommon risks at this insertion site include minor bleeding and bruising (hematoma). More serious complications, such as vessel injury, are reported to occur rarely.
Q: What is meant by a 'Child-Pugh Class A or B' classification for TACE eligibility?
The Child-Pugh score is a widely used system to assess how well the liver is functioning, often required for eligibility screening. Patients classified as Class A have near-normal liver function, while Class B indicates mild to moderate impairment. TACE is generally considered an option for patients who demonstrate well-preserved liver function (Class A or selected Class B).
Q: Is TACE sometimes used as a bridge to a liver transplant?
Studies and clinical guidelines confirm TACE may be used as a bridging therapy for suitable liver cancer patients. The goal is to control the tumor's growth and maintain it within defined criteria while the patient is waiting to undergo a liver transplant procedure.
Q: Can TACE be used to shrink a tumor before surgery or ablation?
Official treatment strategies indicate that TACE may be used to downstage a tumor, meaning the procedure is performed to shrink a tumor that is initially too large. This may potentially make the patient eligible for subsequent curative treatments, such as surgical removal (resection) or local ablation.
Q: Are there different types of TACE, such as conventional TACE versus DEB-TACE?
There are two widely recognized types of the procedure: Conventional TACE (cTACE), which uses an oil-based carrier (Lipiodol) mixed with the chemotherapy, and Drug-Eluting Bead TACE (DEB-TACE), which uses microspheres that slowly release the chemotherapy drug into the tumor.
Q: What does it mean if a tumor becomes refractory to TACE treatment?
In clinical contexts, a tumor is often described as refractory if it shows little to no response to a treatment, or if the disease continues to progress despite adequate courses of TACE. This outcome is often associated with the consideration of alternative therapies or treatment strategies.
Q: How many TACE sessions or courses can a patient typically receive?
Official guidelines do not define a specific maximum number of procedures a person may receive. The procedure is often repeated, and the decision to proceed with subsequent sessions is guided by an assessment of the tumor's response and the impact on the patient's liver function.
Q: Why might a doctor choose TACE over ablation for certain tumors?
International treatment guidelines indicate that the choice between TACE and other localized treatments like ablation is based on several factors. These include the size of the tumor, its specific location within the liver (such as proximity to major blood vessels), and the patient's overall health and liver function.
Q: Is TACE ever combined with other treatments like Sorafenib or immunotherapy?
Studies and official information indicate TACE has been investigated and used in combination with systemic therapies. For example, it is sometimes used alongside oral medications like the multikinase inhibitor Sorafenib, particularly in scenarios involving more advanced stages of the disease.
Q: Why do some TACE procedures use oil (Lipiodol) with the chemotherapy drug?
In conventional TACE (cTACE), an iodized oil called Lipiodol is used to mix with the chemotherapy agent. Official guidelines note that Lipiodol acts as a carrier, selectively concentrating within the tumor, which helps improve the retention time and local concentration of the drug at the treatment site.
Q: What are the differences in side effects between DEB-TACE and conventional TACE?
Comparative studies indicate that Drug-Eluting Bead TACE (DEB-TACE) may be associated with a reduced frequency of systemic reactions and hepatotoxicity (liver damage) compared to Conventional TACE (cTACE). This is attributed to the slower, more controlled release of the chemotherapy drug directly at the treatment site.
Q: Can TACE be used for tumors that have invaded the portal vein (PVTT)?
The use of TACE for tumors that have invaded the portal vein, known as Portal Vein Tumor Thrombus (PVTT), has been increasingly investigated in clinical settings. While traditional guidelines often suggest systemic therapy for this condition, TACE is used in select, typically more localized cases, sometimes combined with other agents.
Q: How does the TACE procedure compare to Hepatic Arterial Infusion Chemotherapy (HAIC)?
Hepatic Arterial Infusion Chemotherapy (HAIC) involves continuously infusing chemotherapy into the liver artery, typically with an implanted pump. Unlike TACE, which uses a blocking material to cut off blood flow, HAIC focuses on drug infusion and does not include the embolization component.
Q: Do the embolization materials (beads/coils) remain in the body permanently?
The fate of the embolic materials depends on the type used. Materials can be either temporary (such as gelatin sponge, which is designed to be absorbed by the body over time) or permanent (such as certain microspheres or coils).
Q: Why is a responsible adult required to stay with the patient overnight after TACE?
The procedure typically involves an overnight hospital stay for close monitoring. This is necessary because of the use of mild sedation and the need to watch for expected reactions like pain, nausea, and fever, which are part of Post-Embolization Syndrome, as well as checking for early complications.
Q: Why does the procedure sometimes require the patient to lie flat for several hours afterward?
Lying flat for several hours is a common instruction if the catheter was inserted via the femoral artery (in the groin). This position helps apply pressure to the artery to prevent bleeding or the formation of a clot at the puncture site following the catheter's removal.
Q: Does the injection of the contrast dye during the procedure cause any side effects?
As with all procedures using contrast dye (angiography), official information notes a risk of adverse reactions. These may include a temporary, immediate sensation of warmth during injection, an allergic reaction, or, for patients with prior kidney issues, potential kidney damage.
Q: Is it possible to receive TACE as an outpatient treatment?
TACE is typically performed in a dedicated hospital setting. Patients are generally admitted to the hospital and require an overnight stay for observation. This is necessary for managing the immediate, expected side effects (Post-Embolization Syndrome) and ensuring safe recovery.
Q: Is it common to experience a temporary loss of appetite after TACE?
Yes, loss of appetite (anorexia) is a commonly reported side effect following the TACE procedure. This is typically temporary and often resolves on its own within one to two weeks after the treatment.
Q: Is there a maximum tumor size or number for a person to be considered for TACE?
Official treatment guidelines typically recommend TACE for patients in the intermediate stage of disease. While assessment is individualized, some commonly used criteria indicate that tumors with a diameter of leq 7 cm or whose total number of lesions is leq 5 are commonly considered when assessing patient suitability.
